Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Dushyant V. Sahani(Brigham and Women's Hospital), Jeffrey A. Meyerhardt(CancerCare), Susan Sheehan(Jackson Laboratory), Pankaj Bhargava(University of North Carolina at Chapel Hill), Avinash Kambadakone(Harvard University), Thomas A. Abrams(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), Kerry Horgan(Beth Israel Deaconess Medical Center), Jennifer A. Chan(University of Calgary), David P. Ryan(East Carolina University), Sanjay Jain(Washington University in St. Louis), Keith Stuart(Brigham and Women's Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Eunice L. Kwak(Harvard University), Alona Muzikansky(Johns Hopkins University), Jill N. Allen(Harvard University), Hui Zheng(Harvard University)
Cited by 308
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k